Documents

CS0050

Sigma-Aldrich

Retinoblastoma ELISA human

sufficient for 96 multiwell tests

Synonym(s):
Retinoblastoma ELISA, Rb ELISA
Pricing and availability is not currently available.

usage

sufficient for 96 multiwell tests

shipped in

wet ice

storage temp.

2-8°C

Gene Information

human ... RB1(5925)

General description

A solid phase sandwich enzyme-linked immunosorbent assay (ELISA).

Application

Rb ELISA is designed for the quantitative detection of Rb in human cell lysates independent of its phosphorylation state. It may be used to normalize the results of Phospho-Rb (pSer249/pThr252) ELISA (CS0060).
Designed for the quantitative determination of human retinoblastoma (Rb).

Biochem/physiol Actions

Rb, the tumor suppressor product of the retinoblastoma susceptibility gene, is a 110 kDa protein that plays an important role in regulating cell growth and differentiation. The cell cycle inhibitory function is abrogated when Rb undergoes phosphorylation, catalyzed by the complex of cyclins/cyclin-dependent protein kinases (cdks).

Features and Benefits

The kit offer a fast (total assay time 4 hours), sensitive (sensitivity 0.1 ng/mL for non-phosphorylated and <0.8 units/mL for phosphorylated Rb) and easy alternative to immunoblotting or other bioassays. Precoated plates are provided in the kit, incubations proceed at room temperature and no proprietary equipment is required.

Analysis Note

The sensitivity is ~0.1 ng/mL, 20 times more sensitive than immunoblotting.

Hazard Codes

B

Safety Statement

24/25

RIDADR

UN 3316 9/PG 3

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.